Kuhn A, Hefter H, Ruzicka T, Lehmann P
Hautklinik der Heinrich-Heine-Universität Düsseldorf.
Hautarzt. 2001 Aug;52(8):726-33. doi: 10.1007/s001050170091.
Thalidomide, an oral drug introduced in Germany in 1953 as a mild sedative, was withdrawn from the world market when its teratogenic effect was discovered some years later. It has since been selectively reintroduced to treat a variety of autoimmune or inflammatory diseases such as erythema nodosum leprosum, prurigo nodularis, graft-versus-host disease, and discoid lupus erythematosus (DLE). We report on three patients with long-standing, severe DLE showing no response to systemic first-, second- and third-line treatments. After four weeks of therapy with thalidomide the skin lesions had improved dramatically and after three to six months all three patients responded with an almost complete remission. The side effects of thalidomide, especially somnolence and paresthesias, were minor and well tolerated by the patients. Our data confirm that thalidomide provides one of the most useful therapeutic alternatives for chronic refractory DLE, despite the risks of teratogenicity and polyneuropathy.
沙利度胺是1953年在德国作为一种轻度镇静剂推出的口服药物，几年后发现其致畸作用时，它被撤出了世界市场。此后，它被有选择地重新用于治疗各种自身免疫性或炎症性疾病，如麻风结节性红斑、结节性痒疹、移植物抗宿主病和盘状红斑狼疮（DLE）。我们报告了3例长期患有严重DLE的患者，他们对全身性一线、二线和三线治疗均无反应。使用沙利度胺治疗4周后，皮肤病变有显著改善，3至6个月后，所有3例患者几乎完全缓解。沙利度胺的副作用，尤其是嗜睡和感觉异常，很轻微，患者耐受性良好。我们的数据证实，尽管存在致畸性和多发性神经病的风险，但沙利度胺为慢性难治性DLE提供了最有效的治疗选择之一。
